Clinical Trials Logo

Postprandial Hypotension clinical trials

View clinical trials related to Postprandial Hypotension.

Filter by:
  • None
  • Page 1

NCT ID: NCT06208904 Recruiting - Clinical trials for PostPrandial Hypotension

The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension

GA-21
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The present study investigates the involvement of the gut hormone glucose-dependent insulinotropic polypeptide (GIP) in the pathophysiology of postprandial hypotension (PPH)

NCT ID: NCT05575661 Recruiting - Clinical trials for Post-induction Hypotension

Correlation Between Postprandial Hypotension and Post-induction Hypotension in the Elderly.

Start date: November 7, 2022
Phase:
Study type: Observational

Postprandial hypotension (PPH) and post-induction hypotension (PIH) are very common in the elderly population and are associated with a variety of poor outcomes.The purpose of this study is to investigate the correlation between PPH and perioperative adverse events such as PIH in the elderly.

NCT ID: NCT05334342 Recruiting - Clinical trials for Spinal Cord Injuries

Low-GI Diet vs High-GI Diet in Individuals With SCI

Start date: May 5, 2022
Phase: N/A
Study type: Interventional

The purpose of this pilot research project is to examine the impact of a low-glycemic index (GI) diet on postprandial hypotension and glucose control in individuals with chronic spinal cord injury. The objectives are: 1) To evaluate the effect of the low-GI diet on the magnitude of postprandial systolic blood pressure drop compared to a high-GI control diet. 2)To evaluate the effect of a low-GI diet on postprandial glucose and insulin responses compared to a high-GI control diet.

NCT ID: NCT02043886 Completed - Type 2 Diabetes Clinical Trials

Acarbose, Postprandial Hypotension and Type 2 Diabetes

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Postprandial hypotension carries a risk of significant morbidity and morbidity including syncope, falls, dizziness, fatigue, stroke and myocardial infarction. Current therapy consists of dietary manipulation (smaller meals) caffeine and octreotide injections all of which are suboptimal and poorly studied. The study hypothesis is that administration of Acarbose will decrease the drop in blood pressure and increase in heart rate in response to food in people with Type 2 diabetes. Acarbose suppresses postprandial glycemia be slowing digestion in the small intestine and delaying gastric emptying. This is a placebo-controlled cross over study involving 2 - 4 hour Meal Tests. During the meal tests heart rate, blood pressure, cerebral artery velocity will be measured. During one meal test subjects will receive Acarbose 50 mg po and during the other will receive placebo. Order of treatment assignment will be done in randomized fashion. A total of approximately 200 cc of blood will be drawn during each meal test.